It has been said that the de¢nition of a camel is a horse designed by a committee. It may be that consensus reports share some of the same properties. Hopefully though this will not include the propensity to spit and the equivalent population of £eas.
The original European Cardiac Society (ECS) and American College of Cardiology (ACC) document 1 to reclassify the de¢nition of acute myocardial infarction (AMI) has certainly generated some confusion although much of this is real rather than apparent. The ECS/ACC document is quite categorical in stating that the diagnosis of AMI requires a rise and fall of troponin in the presence of appropriate clinical features. Much of the inability to distinguish the wheat of primary ischaemic cardiac injury (PICI) from the relative cha¡ of secondary ischaemic cardiac injury (SICI) or non-ischaemic cardiac injury (NICI) comes from ignoring this aspect of the de¢nition. Laboratory parsimony, no longer justi¢able (if it ever was) as costs of troponin measurement have fallen, of performing a single troponin determination, has not helped. The report is therefore right to reinforce the importance of the complete clinical picture. The uses of risk scores, as proposed, are a formal way of doing this.
The report also wishes to provide a means to relate the old World Health Organization (WHO) classi¢cation 2 to the new ESC/ACC document. This may be a worthy aim but does su¡er from some problems. The original National Academy of Clinical Biochemists (NACB) document proposed a similar three level diagnostic classi¢cation based on two decision levels. 3 Here emerges the ¢rst problem. When is a necrotic myocyte an infarcted myocyte, and how many infarcted myocytes make a myocardial infarction? Linguistically of course they are the same. As the report points out, the risk of non-ST elevation AMI (STEMI) de¢ned as ECG changes plus elevated troponin is signi¢cant and therefore great care is required in deciding when an infarct is an infarct and when it is 'only' myocyte necrosis. 4 Problems also come in relating back to the old 'gold standard'. The report is opting for use of creatine kinase (CK) as the standard. The use of CK in WHO AMI was superseded by the use of the MB isoenzyme of creatine kinase (CK-MB) in most (non-UK) laboratories as it has always been acknowledged as diagnostically more e⁄cient than CK. The choice of an AMI cut o¡ is problematic. This needs a solid evidence base. There is a large published literature for cTnT and cTnI relating both to WHO-based AMI cut o¡ and to risk strati¢cation. 5 A cut-o¡ of 1 mg/L is proposed for cTnT. The WHO-related AMI cut o¡ from other studies is in the range 0.1^0.2 mg/L. A direct comparison of conventional markers for WHO classi¢cation and cTnT was performed by Gerhardt that showed good but only 90% concordance at a value of 0.4 mg/L.
The data proposing the1.0 cut o¡ is unpublished but proposes the value on the basis of risk equivalence. This is an excellent principle but two factors need to be taken into account. The ¢rst is clinical. There has been a shift in the type of coronary disease and its management. There is an increasing incidence in NSTEMI with fewer patients presenting with classical Q wave AMI. Add to this that interventions result in limitation of infarct size and that treatment with statins, aspirin, beta blockers and ACE inhibitors has reduced patient mortality. So the infarcts of 2004 are not those of 1994 (or even 2000). This is good news for patients, but the choice of a retrospective mortality comparator may be di⁄cult unless appropriate adjustment can be made for changes in the underlying patterns of disease and treatment. On a purely laboratory note, thrombolysis a¡ects the kinetics of CK release, hence peak value.
A second problem arises from changes in assay calibration. The shift in calibration of the cTnTassay to a recombinant human-based calibrator has altered the calibration of the upper range of the assay. In the FRISC study, the risk of cardiac events (cardiac death or myocardial infarction) at 5 months in unstable coronary artery disease was assessed according to cTnT quintiles. 6 The two lowest risk groups (cTnT 50.06 mg/L,4.3% riskand cTnT 0.06^0.18 mg/L,10.5% risk) are una¡ected. The high-risk group, the three highest quintiles correspond to 0.18^0.62 mg/L and above, (risk16.1%) will now readjust to 0.18^0.38 mg/L and above. In this study the greatest individual risk was seen in patients in the band 0.62^2.12 mg/L (20% risk) which now correspond to 0.38^0.9 mg/L. It has been demonstrated that a cTnT 52.8 mg/L can predict a left ventricular ejection fraction (LVEF) of 540% with100% sensitivity and 92.9% speci¢city. 7 Using the new third generation assay, a cTnT of 41.1 mg/L will theoretically predict an LVEF of 540% with similar sensitivity and speci¢city. This recalibration may a¡ect the data on which the assumptions for cut o¡s are based.
The overall thrust of the document in emphasizing the integration of clinical and laboratory data is excellent.Whether one or two cut o¡s are appropriate needs to be debated. What they should be needs to be the subject of wider consensus and a strong evidence base. There is already a Health TechnologyAssessment review of cardiac troponins from Quality Improvement Scotland (www.nhshealthquality.org). Perhaps the Association of Clinical Biochemists (and UK NEQAS) might be further and more widely involved at this point. The use of risk-based cut o¡s is a good concept. Perhaps we can de¢ne a lower limit of troponin in the general chest pain population, rather than the highly selected clinical trial population that does not correspond to a signi¢cant excess risk. A recent published study on cTnI has shown that functional sensitivity cut o¡ and AMI cut o¡ can be related to risk. 8 So, no £eas, now don't spit.
